Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

Phase 2

Completed

• Conditions: Adenocarcinoma, Bronchiolo-Alveolar
• Interventions: Drug: paclitaxel + carboplatine; Drug: erlotinib

• Registration Number: NCT00384826
• Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Brief Summary

To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-09
• Study First Submitted: 2006-10-05
• Study First Submitted QC: 2006-10-05
• Study First Posted: 2006-10-06
• Primary Completion: 2014-02
• Study Completion: 2014-02
• Status Verified: 2015-02
• Last Update Submitted: 2015-02-12
• Last Update Posted: 2015-02-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 133

Inclusion Criteria

• CBA histologically proven (or cytologically with pneumonic presentation) PS < 3 signed and written informed consent

Exclusion Criteria

• visible tumoral lesion in bronchial fibroscopy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
2	paclitaxel + carboplatine	-
1	erlotinib	-

Primary Outcome Measures

Name	Time	Method
16-week Disease Control Rate	4-week

Trial Locations

Locations (9)

CHU - Pneumologie; 🇫🇷 Caen, France

Centre F. Baclesse; 🇫🇷 Caen, France

Centre Hospitalier - Pneumologie; 🇫🇷 Belfort, France

APHP - CHU Avicenne - Oncologie Medicale; 🇫🇷 Bobigny, France

CHU Grenoble - pneumologie; 🇫🇷 Grenoble, France

CHU Lyautey - Pneumologie; 🇫🇷 Strasbourg, France

APHP - Hopital Tenon - Pneumologie; 🇫🇷 Paris, France

Institut de Cancérologie de la Loire; 🇫🇷 Saint-priest En Jarez, France

APHP - Saint-Antoine - pneumologie; 🇫🇷 Paris, France